Anzeige
Mehr »
Donnerstag, 22.01.2026 - Börsentäglich über 12.000 News
$95 Silber explodiert - Prince Silver vor dem nächsten Durchbruch!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
20 Leser
Artikel bewerten:
(0)

UTM' and ESwab' Are Ideal Collection and Transport Systems for Diagnosis of Patients with Whooping Cough

MURRIETA, Calif., July 9, 2014 /PRNewswire/ -- Whooping Cough is a highly contagious respiratory infection caused by bacteria named Bordetella pertussis. Whooping Cough is a vaccine preventable disease that is spreading rapidly. In fact, the US Health Department is calling it "a problem of epidemic proportions[i]" in the state of California. The epidemic is not limited to California. The Centers for Disease Control (CDC) have reported that from January 2014 to June 2014 there has been 9,964 cases of Whooping Cough "reported to CDC by 50 states and Washington, D.C.; this represents a 24% increase compared with the same time period in 2013.[ii]"

ESwab' is designed to maintain the viability of aerobic, anaerobic and fastidious bacteria. In a study, titled "ESwab' System for Bordetella Testing," presented by Ken Van Horn, Carol Audette and Lamela Umaru during the American Society for Microbiology 111th General Meeting, in May 2011, it was concluded that "ESwab' maintains sufficient B. pertussis and B. parapertussis viability to permit detection in culture and preserves cell and DNA integrity for DFA and PCR detection after 96 hours of refrigerated storage[iii]."

In some occasions, patients exhibiting symptoms of bacterial Whooping Cough may also be coinfected with common respiratory viruses. Ina child presenting with a respiratory infection the causative agent could be bacterial (Bordetella) or viral if the symptoms are not clear cut. UTM' Universal Transport Medium is a viral transport medium, manufactured by COPAN, for collection, transport, maintenance and long term freeze storage of Viruses, such as influenza. A recent study, published in the Journal of Clinical Microbiology, titled "Comparative Evaluation of the Diagenode Multiplex PCR Assay on the BD Max System versus a Routine In-House Assay for Detection of Bordetella pertussis," shows the versatility of UTM' as a collection and transport system. UTM' was used to transfer the specimens, and from the positive specimens "42.1% were coinfected with respiratory viruses" as well as bacterial Bordetella pertussis[iv]. Another study published in the Journal of Clinical Microbiology titled "Comparison of Rates of Positivity for Bordetella pertussis by Real-Time PCR between Specimens Collected with Rayon Swabs on Aluminum Wire Shaft in Amies Gel with Charcoal and Specimens Collected with Flocked Swabs in Universal Viral Transport Medium during an Epidemic[v]" coincides with the findings of the previously mentioned article. In fact, it concludes that "a comparison of real-time PCR positivity rates for Bordetella pertussis between specimens collected with rayon swabs on an aluminum wire shaft in Amies gel with charcoal and those collected with flocked swabs in universal viral transport medium [UTM'] during an epidemic revealed that their performances were comparable. Both publications find UTM' is a cross platform medium proven to be good for viruses, as well as Bordetella. COPAN's complete array of products have a proven track record, through numerous clinical and scientific publications, demonstrating their high quality and reliability. COPAN has experience responding to epidemics, like Whooping Cough, by producing products for specimen collection and transport in a timely manner.

Whooping Cough is a preventable disease. Babies, in particular, are a population that needs protection because of the highly contagious nature of the bacterial disease. In fact, if babies 1 year or younger catch Whooping Cough repercussion can be severe, with half of them ending up in hospitals. The CDC suggests that "you can protect babies from Whooping Cough by getting your vaccine and making sure your baby gets [the] vaccines[vi]."

About COPAN Group

With a reputation for innovation, COPAN is the leading manufacturer of collection and transport systems in the world. COPAN's collaborative approach to pre-analytics has resulted in Flock Swabs, ESwab, UTM' and modular laboratory automation, WASP® and WASPLab'. For more information about COPAN Group, visit http://www.copaninnovation.com.

[i] Christensen, Jen. California declares Whooping Cough epidemic. CNN. June 16, 2014. http://www.cnn.com/2014/06/13/health/whooping-cough-california/ Accessed 7/7/2014.

[ii] Pertussis Outbreak Trends. CDC. http://www.cdc.gov/pertussis/outbreaks/trends.html. Accessed 7/7/2014.

[iii] Van Horn, Ken et al. ESwab' System for Bordetella Testing. Poster Session ASM - 111th General Meeting, May 2011, New Orleans, LA.

[iv] Kenicer, Juliet et al.Comparative Evaluation of the Diagenode Multiplex PCR Assay on the BD Max System versus a Routine In-House Assay for Detection of Bordetella pertussis. doi: 10.1128/JCM.00212-14 J. Clin. Microbiol. July 2014 vol. 52 no. 7 2668-2670.

[v] Arbefeville, Sophie and Patricia Ferrieri. Comparison of Rates of Positivity for Bordetella pertussis by Real-Time PCR between Specimens Collected with Rayon Swabs on Aluminum Wire Shaft in Amies Gel with Charcoal and Specimens Collected with Flocked Swabs in Universal Viral Transport Medium during an Epidemic. doi: 10.1128/JCM.01070-14 J. Clin. Microbiol. July 2014 vol. 52 no. 7 2656-2658.

[vi] "Protect Babies from Whooping Cough (Pertussis)." CDC. http://www.cdc.gov/features/pertussis/. February 10, 2014. Accessed 7/7/2014.

SOURCE COPAN Group

© 2014 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.